Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627) Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Brain Neoplasms
  • Dasatinib
  • Glioblastoma

abstract

  • Intraparticipant dose escalation was feasible, but dasatinib was ineffective in recurrent GBM. Clinical trials.gov identified. NCT00423735 (available at http://clinicaltrials.gov/ct2/show/NCT00423735).

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/neuonc/nov011

PubMed ID

  • 25758746

Additional Document Info

start page

  • 992

end page

  • 8

volume

  • 17

number

  • 7